Member Info for Del77

Parker was appointed in May 2016 . The deal was negotiated by CRT Pioneer fund in Sept 2016 with Sierra . I personally do not believe that Sareum had a significant contribution to the negotiations , which were completed by the CRT Pioneer fund from reading the rns in sept 2016. I do hope however since then Parker has been busy negotiating with a big pharma on a deal with tyk2. It will be interesting to see if any progress has been made when the interims are announced in the next week or so. The delay in announcing the interims must in my mind relate to confirmation of the size of a further instalment in respect of CHK1 from Sierra. The unknown is how Sareum plan to spend the funds to progress tyk2 and Aurora+. One question i keep asking myself how long is it before Tim needs for Sareum to be sold from his own personal circumstances as he approachs an age where he could chose to think about retiring D:

I am very optimistic for news updates in the next 4 weeks, which i think will be pivotal to the future direction of Sareum. I think Stephen Parker was brought in to ‘commercialise the work of Tim Mitchell and John Reader . Tim is 55 years old and will not have a full final salary pension scheme unlike a lot of his peer group in the nhs and university sector , some of colleagues and peer group will be thinking of slowing down towards retirement. Tims pension is likely to depend to a large degree on selling Sareum shares at a significantly higher price that 0.925 a share. This is a high risk position Tim finds himself in. The ideal solution for Tim (and all investors )is for Stephen Parker ti secure a takeover of Sareum. Tim continues his research / development and at the same time de risks his personal finances and a time of life he needs to. Continuing to raise capital through placing of shares will in the short term lower the share price with no certainty of future success. I do hope Stephen Parker has been very busy since appointment to Sareum I think we wil find out soon GLA. D

It is interesting to note that Summ is up 6.5% on the nasdaq this evening , although their is no change to Sarepta share price. This is the first time i have noticed this recently.. it is usually the case Sarepta share price movement is well ahead of Summit. Could this mean that US investors are starting to take note and value progress made by Summits DMD 24 week clinical trial ahead of Sarepeta solution that only helps 13% of the boys affected by this terrible illness. D

Stevej Great to see you posting again today I remember your posts were really knowledgable and constructive over many years which helped with my confidence to remain invested through the spike and the low point at 0.20 when i added a good few. Sadly did not sell on the spike beforehand at 4.5p. I now hold a sizeable holding which i ideally need to top slice on any spike, as i have now retired. The next 4 weeks will be really interesting with news from Sierra and how this impacts on our own compounds development and potentially any licencing deal. Good luck .D

Glynn Edwards comment ...A small chance we could take DMD to markets in months . What would that do to the share price ( absolutely mega .. just look at Sarepta mkt cap!!) and the families and boys so effected by this condition. D

0.94 pence paid:)

I find the delay very interesting. Sareum could release the interim financials and in february and a research update at any time. I just wonder if Sareum are currently in discussions with a third party and for regularity compliance purposes need to delay publication of the interims. This may involve Sierra only or and another third party . We will have to wait and see. I have been invested since 2009 and i have to say i am suprised that the share price is not higher at this stage abd looking forward to the next months annoubcements D

What is unusual is today that sales outnumber purchases of shares by roughly 6 to 1, yet the share price has not moved all day. Are market makers holding shares for any news expected early next week? D.

With such good results today why would Sarepta not buy out the dmd programme while summit mkt cap is so low. No further milestone payments ,no future royalty payments, Sarepta just need to fully fund the study costs. gla. Any delays may result in a higher buy out figure . GLA . D.

Summit on nasdaq is up over5% at usd12.8 on good early volumes Sarepta is also up 3% At over 64usd Is some bring brewing? D

The Americans may be starting to see value in Summit with the nasdaq share price over USD 12 on decent volume, up over5%. It would be great to close above USD 12 tonight . D

Summit up 6% on nasdaq with high volume GLA. D

Interesting on the Nasdaq today Sarepta shares premarket are up to usd59.25 52 week high,compared to a 52 week low of usd 26.5 .Something is driving the share price. It would be nice to know what it is ? D

If this is the strategy , imho it may be, Sarepta would not raise funds c 12 months in advance... 6 months possibly , suggesting may / June 2018 as a possible timescale . Leaving it to Dec after the 48 week data is available may be very costly to Sarepta , they may prefer a cheaper price and take the risk. Also you wonder why the appointment of a joint broker in nov 2017 disclosed as a misc rns suggesting a low key announcement and not with a more positive title ‘appointment of new joint broker’ , in order not to bring any attention to a potential split of summit into two companies and possibly an acquisition of the dmd arm by sarepta. D

A possible take away from todays presentation for me is that Summit have a very good idea of the 24 week results as do Sarepta . Sarepta raised substantial funds late last year, Summit appointed a joint broker at the same time .Glynn answering the final question from a strategy perspective whether summit would continue with DMD and Cdiff, yes but review in late 2018 when 48 week results are known My gut feeling is that Sarepta will make a bid for the dmd business in Q1 when the 24 weeks data is known , if it is as good as we all hope the results are. D.

At least our recently appointed broker Panmure Gordon are promoting summit in the Telegraph. With all the American politics surrounding DMD and Sarepta i think we will see Summits split intotwo companies with DMD bought out by Sarepta during 2018, especially now Summit has strenghed it antibiotics business with the purchase of Discuva.D

The nasdaq trades on tuesday and the FTSE trades next on wednesday . D

Is the increase in the share price today in any way connected to tomorrows fireside presentation. Will have to wait and see D

Pleasing to see that management are raising the profile of summit in the US at two forthcoming investor presentations over the next two weeks

Smmt on nasdaq + 6% in early and low volume trading